Pitavastatin demonstrates no significant drug-to-drug interaction when administered with CYP3A4 inhibitors

Pitavastatin demonstrates no significant drug-to-drug interaction

25.08.2009

Pitavastatin demonstrates no significant drug-to-drug interaction when administered with CYP3A4 inhibitors. Data shows potential tolerability advantage for pitavastatin compared with other statins.

BARCELONA, 2nd September 2009 - New data presented at the European Society of Cardiology congress (ESC) demonstrated that the co-administration of the cytochrome inhibitor itraconazole has no clinically relevant effect on the pharmacokinetics of pitavastatin, in healthy volunteers.

Download Material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X